5. Legal concerns In the future there may be consumer products which require implantation of non‑therapeutic BCIs involving a medical procedure (e.g. surgery to insert an implant into the brain). This will require a surgeon to obtain informed consent regarding the procedure to insert the device, but not the operation and terms and conditions relating to the device once it has been implanted. In these circumstances consumers will need to be aware of key issues in deciding to implant a device – including service life, the availability of spare parts, changes in company ownership, retention, ownership and security of neural data and what will happen if the company responsible for the device has been deregistered. Significant decisions, such as this, ought not be left to template consumer‑oriented contracts with fine print terms. Medical regulation There are already medical/therapeutic regulations which could usefully be applied to the development, testing and use of neurotechnologies in medical applications. In Australia the Therapeutic Goods Act 1989 (Cth) governs products defined as therapeutic goods, which can include medicines, medical devices and biologicals in Australia. The Therapeutic Goods Regulations 2002 (Cth) intend to regulate medical devices from the perspective of the physical safety of a user. The Therapeutic Goods Administration (TGA) is the authority responsible for evaluating, assessing and monitoring products that are defined as therapeutic goods. The TGA regulate medicines, medical devices and biologicals to help Australians stay healthy and safe.234 It is possible that many neurotechnologies will start as medical products which hopefully fall within the ambit of Australia’s medical regulations laws. However, questions remain about what happens which such products are pivoted away from medical applications to consumer markets (where less protection exists). There certainly appears to be a regulatory gap between the protections applied to medical and consumer neurotechnological products which must be addressed. Australian Consumer Law The Australian Consumer Law (ACL) is contained in schedule 2 of the Competition and Consumer Act 2010 (Cth) and will likely apply to consumer neurotechnologies not otherwise captured by specialist product safety regimes that regulate medical devices and therapeutic goods. Certain protections of the ACL are only applicable to conduct in respect of ‘consumers’.235 Where an individual purchases neurotechnological product they may meet the statutory definition of ‘consumer’ provided the price of which is less than $100,000 AUD.236 The ACL includes consumer guarantees which are basic rights that businesses must meet when they sell products or services. These basic rights include ensuring a product sold to a consumer is of acceptable quality and fit for purpose.237 Acceptable quality means that a neurotechnological product: ƒ is safe, durable and free from defects ƒ has an acceptable appearance and finish ƒ does everything that similar products are commonly used for.238 However there are no set rules for deciding whether a neurotechnological product is of acceptable quality, or how long it should last. To determine if a neurotechnological product meets acceptable quality, the following factors need to be considered: ƒ What kind of product is it, and how does it compare to similar products? ƒ What is it made of and how was it made, and how does this compare to similar products? ƒ How much did it cost, and how does it compare to products of a similar price? ƒ What maintenance may be needed to keep the product operating? ƒ Did the business or manufacturer make any claims about quality, or how long the product could last for? ƒ Did the business warn the consumer about any defects, or warn against the product’s use in a certain manner? Australian Human Rights Commission 31

Select target paragraph3